Shares of Novo Nordisk (NOVOB.DK) rose by more than 10% following the publication of early-phase clinical trial results for a new obesity treatment. The study focused on a substance called amycretin, a unimolecular GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous administration.
According to the results, patients experienced a 9.7% reduction in body weight after 20 weeks, 16.2% after 28 weeks, and 22.08% after 36 weeks. In contrast, those treated with placebo saw an estimated weight gain of 1.9%, 2.3%, and 2.0%, respectively.
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appBased on these findings, Novo Nordisk plans to further develop amycretin clinically for adults with overweight or obesity.
The company's stock surged by over 10% following news of the successful clinical trial results. Novo Nordisk has been in a downward trend since mid-2024, at one point falling below 550 DKK, a level last seen before the publication of the first significant studies on the potential impact of the drug Wegovy on reducing the risk of heart disease in patients, which the company presented in August 2023. Source: xStation.
